Loading…

Neurogene Inc.NGNECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 21
Mkt cap
$479M
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$7.32M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.7%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · USD$23.14
1D+0.2%
1W-7.8%
1M-8.9%
3M-39.1%
6M-14.1%
YTD+12.3%
1Y+3.0%
ATR %9.2%
Beta1.45
52w lowhigh47.0% off high

What Neurogene does

Employees: 131

Neurogene at a glance

Size Neurogene (NGNE) is a United States Health Care company (Biotechnology) with a market value of $479M, the 2699th largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.14 on 18 Nov 2026.

Performance Over six months the shares fell 14.1%, against -5.6% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 18 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median -4.0%).

Short interest Short interest is 28.4% of the free float (30 Oct 2026).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026Peer median 90NGNE 84
Six months, rebased to 100: Neurogene against the median of its 20 peers (local-currency closes).

Neurogene financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$925,000$0$0
Revenue growth—-100%———
Gross profit-$3.27M-$3.19M-$2.32M-$3.26M-$3.20M
EBITDA-$127M-$100M-$79.4M-$52.3M-$53.3M
Net income-$119M-$90.4M-$75.1M-$36.3M-$55.2M
Free cash flow-$95.9M-$78.4M-$71.4M-$51.7M-$55.1M
Capital expenditure$1.05M$1.18M$808,000$321,000$2.23M
Total debt$7.55M$9.89M$12.4M$15.0M$249M

Quarterly statements and history in the cockpit →

Neurogene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%MNPR4147CBIOFENC6586603255KMDA688247DMAC300858STTK041960VLA115180NGNE6-month return →1-month return →
Up and to the right = strong over both horizons. Neurogene is the large dot.

Neurogene competitors and peer comparison

How Neurogene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neurogene against its 20 peers (data as of 18 Nov 2026)
MeasureNGNEPeer medianRank in peer set
1-month return-8.9%-11.1%9th highest of 21
6-month return-14.1%-5.6%9th lowest of 18
Distance from 52-week high-47.0%-44.6%9th lowest of 21
Revenue growth (TTM)-100.0%-4.0%2nd lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a

Questions

Which companies are Neurogene's closest peers?
The cockpit's peer set: Monopar Therapeutics (MNPR), TaiMed Biologics (4147.TWO), Crescent Biopharma (CBIO), Fennec Pharmaceuticals (FENC), CHO Pharma (6586.TWO), TenNor Therapeutics Suzhou (6872.HK), Liaoning Dingjide Petrochemical (603255.SS), Kamada (KMDA).
How has Neurogene stock performed?
Over six months to 18 Nov 2026 the shares returned -14.1% against -5.6% for the median peer; over one year +3.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.